fleroxacin has been researched along with Escherichia coli Infections in 7 studies
Fleroxacin: A broad-spectrum antimicrobial fluoroquinolone. The drug strongly inhibits the DNA-supercoiling activity of DNA GYRASE.
fleroxacin : A fluoroquinolone antibiotic that is 4-oxo-1,4-dihydroquinoline which is substituted at positions 1, 3, 6, 7 and 8 by 2-fluoroethyl, carboxy, fluoro, 4-methylpiperazin-1-yl and fluoro groups, respectively. It is active against many Gram-positive and Gram-negative bacteria.
Escherichia coli Infections: Infections with bacteria of the species ESCHERICHIA COLI.
| Excerpt | Relevance | Reference |
|---|---|---|
| "A clinical study was conducted on fleroxacin (FLRX) in 143 patients and carriers with infectious enteritis (shigellosis, Salmonella enteritis, Campylobacter enteritis, pathogenic Escherichia coli enteritis, Vibrio parahaemolyticus enteritis, cholera, multiple bacterial infections, pathogen-negative enteritis)." | 9.07 | [Basic and clinical studies of fleroxacin on infectious enteritis. Research Group of AM-833 on infectious enteritis]. ( Ajisawa, A; Masuda, G; Murata, M; Negishi, M; Nitta, Y; Sagara, H; Takizawa, Y; Tomizawa, I; Tsunoda, T; Yamaguchi, T, 1994) |
| "A clinical study was conducted on fleroxacin (FLRX) in 143 patients and carriers with infectious enteritis (shigellosis, Salmonella enteritis, Campylobacter enteritis, pathogenic Escherichia coli enteritis, Vibrio parahaemolyticus enteritis, cholera, multiple bacterial infections, pathogen-negative enteritis)." | 5.07 | [Basic and clinical studies of fleroxacin on infectious enteritis. Research Group of AM-833 on infectious enteritis]. ( Ajisawa, A; Masuda, G; Murata, M; Negishi, M; Nitta, Y; Sagara, H; Takizawa, Y; Tomizawa, I; Tsunoda, T; Yamaguchi, T, 1994) |
| " A rabbit model of CAUTI using a closed urinary catheter drainage system and the mutant strain of Escherichia coli (WE 6933) were used to examine three dosage regimens (30 mg/kg q8h i." | 1.29 | Therapeutic efficacy of fleroxacin for eliminating catheter-associated urinary tract infection in a rabbit model. ( Cleeland, R; Costerton, JW; Lam, K; McKay, SG; Morck, DW; Olson, ME; Prosser, B, 1993) |
| "[18F]fleroxacin was synthesized and shown to be identical physically, chemically, and in its antimicrobial activity to the commercially produced product." | 1.29 | Pharmacokinetics of fleroxacin as studied by positron emission tomography and [18F]fleroxacin. ( Alpert, NM; Babich, J; Callahan, RJ; Cleeland, R; Correia, JA; Liu, YY; Livni, E; Prosser, B; Rubin, RH; Tham, E, 1993) |
| "Fleroxacin was more potent than norfloxacin." | 1.27 | Comparative activities of norfloxacin and fleroxacin in experimental infections due to Salmonella typhimurium and Escherichia coli. ( Fabrig, J; Hof, H, 1988) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (14.29) | 18.7374 |
| 1990's | 6 (85.71) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Albrecht, HA | 1 |
| Beskid, G | 1 |
| Chan, KK | 1 |
| Christenson, JG | 1 |
| Cleeland, R | 4 |
| Deitcher, KH | 1 |
| Georgopapadakou, NH | 1 |
| Keith, DD | 1 |
| Pruess, DL | 1 |
| Sepinwall, J | 1 |
| Sagara, H | 1 |
| Tomizawa, I | 1 |
| Takizawa, Y | 1 |
| Nitta, Y | 1 |
| Tsunoda, T | 1 |
| Yamaguchi, T | 1 |
| Masuda, G | 1 |
| Negishi, M | 1 |
| Ajisawa, A | 1 |
| Murata, M | 1 |
| Morck, DW | 1 |
| Olson, ME | 1 |
| McKay, SG | 1 |
| Lam, K | 1 |
| Prosser, B | 2 |
| Costerton, JW | 1 |
| Rubin, RH | 1 |
| Livni, E | 2 |
| Babich, J | 2 |
| Alpert, NM | 2 |
| Liu, YY | 2 |
| Tham, E | 1 |
| Callahan, RJ | 2 |
| Correia, JA | 2 |
| Georgopoulos, A | 1 |
| Feistauer, SM | 1 |
| Graninger, W | 1 |
| Pfleger, S | 1 |
| Georgopoulos, M | 1 |
| Fischman, AJ | 1 |
| Thom, E | 1 |
| Prosser, BL | 1 |
| Hof, H | 1 |
| Fabrig, J | 1 |
1 trial available for fleroxacin and Escherichia coli Infections
| Article | Year |
|---|---|
[Basic and clinical studies of fleroxacin on infectious enteritis. Research Group of AM-833 on infectious enteritis].
Topics: Adolescent; Adult; Aged; Campylobacter Infections; Drug Administration Schedule; Dysentery, Bacillar | 1994 |
6 other studies available for fleroxacin and Escherichia coli Infections
| Article | Year |
|---|---|
Cephalosporin 3'-quinolone esters with a dual mode of action.
Topics: Animals; Anti-Infective Agents; Cefotaxime; Cephalosporins; Chemical Phenomena; Chemistry; Ciproflox | 1990 |
Therapeutic efficacy of fleroxacin for eliminating catheter-associated urinary tract infection in a rabbit model.
Topics: Animals; Catheters, Indwelling; Disease Models, Animal; Escherichia coli Infections; Fleroxacin; Mal | 1993 |
Pharmacokinetics of fleroxacin as studied by positron emission tomography and [18F]fleroxacin.
Topics: Animals; Escherichia coli Infections; Fleroxacin; Fluorine Radioisotopes; Male; Mice; Muscular Disea | 1993 |
Antibacterial activity of sparfloxacin against experimental renal infections in mice.
Topics: Abscess; Animals; Anti-Infective Agents; Ciprofloxacin; Escherichia coli Infections; Female; Fleroxa | 1992 |
Pharmacokinetics of 18F-labeled fleroxacin in rabbits with Escherichia coli infections, studied with positron emission tomography.
Topics: Animals; Escherichia coli Infections; Fleroxacin; Male; Mice; Rabbits; Rats; Rats, Sprague-Dawley; S | 1992 |
Comparative activities of norfloxacin and fleroxacin in experimental infections due to Salmonella typhimurium and Escherichia coli.
Topics: Animals; Anti-Infective Agents; Ciprofloxacin; Escherichia coli Infections; Female; Fleroxacin; Mice | 1988 |